Ad
related to: Sinovac BiotechLearn How Genmab is Driving the Next Generation of Antibody-Based Medicine. Explore Genmab's Unique Platforms for Creating Enhanced Antibodies.
- Careers
Join our Mission to Improve
the Lives of Patients.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Sign Up
Sign Up for Updates, News
and Much More.
- Careers
Search results
SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
Sinovac Biotech Ltd. (Chinese: 科兴控股生物技术有限公司) is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases.
- Who Can Be Vaccinated?
- Should Pregnant and Breastfeeding Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- Is It Safe?
- How Efficacious Is The Vaccine?
- What Is The Recommended Dosage?
- Is A Booster Dose Recommended For This Vaccine?
- Can This Vaccine Be ‘Mixed and Matched’ with Other Vaccines?
- Does It Prevent Infection and Transmission?
- Does It Work Against New Variants of Sars-Cov-2 Virus?
- GeneratedCaptionsTabForHeroSec
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and the WHO Values Framework, older adults, health workers and immunocompromised persons should be prioritised. The Sinovac vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vacci...
The available data on the Sinovac-CoronaVac (COVID-19) vaccine in pregnant women are insufficient to assess either vaccine efficacy or possible vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is commonly used in many other vaccines with a well-documented safety profile, such as Hepatitis ...
The vaccine is not recommended for persons younger than 18 years of age, pending the results of further studied in that age group. Individuals with a history of anaphylaxis to any component of the vaccine should not take it. Persons with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from acute illness and the...
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above. Safety data is currently limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared...
A large phase 3 trial in Brazil showed that two doses, administered at an interval of 14 days, had an efficacy of 51% against symptomatic SARS-CoV-2 infection, 100% against severe COVID-19, and 100% against hospitalization starting 14 days after receiving the second dose.
SAGE recommends the use of Sinovac-CoronaVac vaccine as 2 doses (0.5 ml) given intramuscularly. SAGE recommends that a third, additional dose of the Sinovac vaccine be offered to persons aged 60 and above as part of an extension of the primary series. Current data does not indicate the need for an additional dose in persons under 60 years of age. S...
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap. The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 i...
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series. To ensure equivalent or favourable immunogenicity or vaccine effectiveness either of the WHO EUL COVID-19 mRNA vaccines (Pfizer or Moderna) or the WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD or Janssen) can be used as a second dos...
There is currently no substantive data available related to the impact of COVID-19 vaccine Sinovac-CoronaVac on transmission of SARS-CoV-2, the virus that causes COVID-19 disease. In the meantime, WHO reminds of the need to stay the course and continue practicing public health and social measures that should be used as a comprehensive approach to p...
In an observational study, the estimated effectiveness of Sinovac-CoronaVac in health workers in Manaus, Brazil, where P.1 accounted for 75% of SARS-CoV-2 samples was 49.6% against symptomatic infection (4). Effectiveness has also been shown in an observational study in Sao Paulo in the presence of P1 circulation (83% of samples). There are still i...
Learn about the safety, efficacy, dosage, and use of the Sinovac-CoronaVac vaccine against COVID-19 from WHO. Find out who can be vaccinated, who should not, and how to mix and match with other vaccines.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella ...
Dec 24, 2020 · The private Chinese company Sinovac developed a coronavirus vaccine called CoronaVac. The vaccine is approved for use in China and authorized for emergency use in more than a dozen other...
Jun 1, 2021 · WHO recommends the Sinovac-CoronaVac vaccine for adults 18 years and older, based on its safety, efficacy and quality. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac and has easy storage requirements.
People also ask
Who is Sinovac Biotech?
What does Sinovac stand for?
What is Sinovac Biotech's coronavac?
How do I contact Sinovac Biotech?
Feb 6, 2021 · Sinovac Biotech said on Saturday that its unit's COVID-19 vaccine has been approved for use by the general public by China's medical products regulator.
Ad
related to: Sinovac BiotechLearn How Genmab is Driving the Next Generation of Antibody-Based Medicine. Explore Genmab's Unique Platforms for Creating Enhanced Antibodies.
